AFMD (Affimed NV) יחס שווי שוק לשווי בספרים

The current price-to-book ratio in the intraday price action on the GURU.Markets chart demonstrates the market valuation of Affimed, where 0.15 shows the current value of the metric. The firm's capital is based on the creation of immune activators for cancer therapy and partner payments. However, the risk of test failure and R&D costs are weighing on margins. Management is currently cutting expenses, adapting programs to a limited budget.

Long-term capital requires strict control over overpayment relative to tangible assets. For Affimed (AFMD), which develops unique methods of immune activation against cancer, the valuation of intellectual property is critically important. The company's valuation history via the P/B ratio compares market value with net assets. A ratio exceeding one indicates market confidence in the future success of the therapy, however, peak values signal increased risks of a correction.